Reem Altaf

Reem Altaf


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
UIUmair Ilyas
Umair Ilyas
MAMuhammad Asif
Muhammad Asif
Minglian WangMinglian Wang
Minglian Wang
RAReem Altaf
Reem Altaf
HZHajra Zafar
Hajra Zafar
MAMuhammad Abbas
Muhammad Abbas
Pioglitazone (PGZ) is utilized as a therapeutic agent in the management of (type 2) diabetes to control blood glucose levels. The existing research work was intended to make and optimize PGZ-containing NLCs (nanostructured lipid carriers). The fabricated nanostructured lipid carrier preparation was optimized by using different concentrations of the surfactants (Tween 80 and Span 80) and solid lipid (Compritol® 888 ATO) and liquid lipid (Labrasol®) while keeping the concentration of drug (PGZ), and co-surfactants (poloxamer 188) the same. The optimized NLC formulation (PGZ-NLCs) was further assessed for physical and chemical characterization, in vitro PGZ release, and stability studies. The optimized PGZ-NLCs have shown an average diameter of 150.4 nm, EE of 92.53%, PDI value of 0.076, and zeta-potential of −29.1 mV, correspondingly. The DSC thermal analysis and XRD diffractograms had not presented the spectrum of PGZ, confirming the comprehensive encapsulation of PGZ in the lipid core. PGZ-NLCs showed significantly extended release (51% in 24 h) compared to the unformulated PGZ. Our study findings confirmed that PGZ-NLCs can be a promising drug delivery system for the treatment of type 2 diabetes.

12 October 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
UIUmair Ilyas
Umair Ilyas
BNBisma Nazir
Bisma Nazir
RAReem Altaf
Reem Altaf
SMSyed Aun Muhammad
Syed Aun Muhammad
HZHajra Zafar
Hajra Zafar
YDYontao Duan
Yontao Duan
In an attempt to find new targets for α-amylase and α-glucosidase for the treatment of type 2 diabetes mellitus, the present study aims in determining the anti-diabetic potential of synthesized dihydropyrimidinone derivatives. The in vitro α-glucosidase and α-amylase inhibitory activity was performed and the molecular docking analysis of the ligand in the active binding site of target protein was determined. The results revealed significant percent inhibition of α-glucosidase by the compound 6-benzyl-4-(4-hydroxyphenyl)-3,4,6,7-tetrahydro-1H-pyrrolo[3,4-d]pyrimidine-2,5-dione (compound A). The active compound showed 81.99% inhibition when compared to standard ascorbic acid having percent inhibition 81.18%. The IC50 of active compound (A) showed to be 1.02 µg/ml. The molecular docking analysis revealed that the ligand bound to the active binding site of protein with the lowest binding energy of -7.9 kcal/mol that was also significantly similar to standard having -7.8 kcal/mol binding energy. The molecular dynamic simulation studies also revealed stable binding of ligand in the active binding site of protein with low RMSD of 1.7 Å similar to the protein RMSD 1.6Å In conclusion, the study revealed a potential new target against α-glucosidase to treat type 2 diabetes mellitus.

25 April 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
RAReem Altaf
Reem Altaf
HNHumaira Nadeem
Humaira Nadeem
UIUmair Ilyas
Umair Ilyas
JIJamshed Iqbal
Jamshed Iqbal
RPRehan Zafar Paracha
Rehan Zafar Paracha
Faisal RazaFaisal Raza
Faisal Raza
The diverse pharmacological role of dihydropyrimidinone scaffold has made it to be an interesting drug target. Because of the high incidence and mortality rate of breast cancer, there is a dire need of discovering new pharmacotherapeutic agents in managing this disease. A series of twenty-two derivatives of 6-(chloromethyl)-4-(4-hydroxyphenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (3a-3k) and ethyl 6-(chloromethyl)-4-(2-hydroxyphenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (4a-4k) synthesized in a previous study were evaluated for their anticancer potential against breast cancer cell line. Molecular docking studies were performed to analyze the binding mode and interaction pattern of these compounds against nine breast cancer target proteins. The in vitro cell proliferation assay was performed against the breast cancer cell line MCF-7. The structure activity relationship of these compounds was further studied using QSARINS. Among nine proteins, the docking analysis revealed efficient binding of compounds 4f, 4e, 3e, 4g, and 4h against all target proteins. The in vitro cytotoxic assay revealed significant anticancer activity of compound 4f having of 2.15 μM. The compounds 4e, 3e, 4g, and 4h also showed anticancer activities with of 2.401, 2.41, 2.47 and 2.33 μM, respectively. The standard tamoxifen showed 1.88 μM. The 2D qualitative structure-activity relationship (QSAR) analysis was also carried out to identify potential breast cancer targets through QSARINS. The final QSAR equation revealed good predictivity and statistical validation and values for the model obtained from QSARINS was 0.98 and 0.97, respectively. The active compounds showed very good anticancer activities, and the binding analysis has revealed stable hydrogen bonding of these compounds with the target proteins. Moreover, the QSAR analysis has predicted useful information on the structural requirement of these compounds as anticancer agents with the importance of topological and autocorrelated descriptors in effecting the cancer activities.

21 September 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
SJSarmad Sheraz Jadoon
Sarmad Sheraz Jadoon
UIUmair Ilyas
Umair Ilyas
HZHajra Zafar
Hajra Zafar
APAna Cláudia Paiva-Santos
Ana Cláudia Paiva-Santos
SKSaifullah Khan
Saifullah Khan
MAMuhammad Abbas
Muhammad Abbas
Glioblastoma multiforme is a serious and life-threatening tumor of central nervous system, characterized by aggressive behavior, poor prognosis, and low survival rate. Despite of the availability of aggressive antitumor therapeutic regimen for glioblastoma (radiotherapy followed by chemotherapeutic dose), recovery rate, and patients’ survival ratio is attributed to the lack of selectivity of therapeutic drugs and less advancement in cancer therapeutics over last decade. Moreover, tools employed in conventional diagnosis of glioblastoma are more invasive and painful, making the process excruciating for the patients. These challenges urge for the need of novel biomarkers for diagnosis, prognosis, and prediction purpose with less invasiveness and more patient compliance. This article will explore the genetic biomarkers isocitrate dehydrogenase mutation, MGMT mutations, and EGFR that can be deployed as an analytical tool in diagnosis of disease and prognosis of a therapeutic course. The review also highlights the importance of employing novel microRNAs as prognostic biomarkers. Recent clinical advancements to treat GBM and to prevent relapse of the disease are also discussed in this article in the hope of finding a robust and effective method to treat GBM.

29 March 2024 in Cukurova Medical Journal
Verified
Journal Article
Open access
PDF file
UIUmair Ilyas
Umair Ilyas
SJSarmad Sheraz Jadoon
Sarmad Sheraz Jadoon
TATanzeel Ahmed
Tanzeel Ahmed
RAReem Altaf
Reem Altaf
Aslam KhanAslam Khan
Aslam Khan
ZKZakir Khan
Zakir Khan
Coronavirus disease 2019 (COVID-19), scientifically known as severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has adversely affect the respiratory system of humans and badly crushed the economies of most developed countries. This study aims to investigate the current COVID-19 situation and therapeutic approaches including non-viral vaccines, efficacy, safety, their trials, dosage protocols and mass vaccination established for COVID-19. A comprehensive literature search was conducted using PubMed, Scopus, Google Scholar, and MEDLINE databases. The title of the research articles were reviewed first, followed by the abstracts and finally the complete studies. This review critically focuses on the damaging effects of COVID-19 and its mutations, multiple variants, pharmacological approaches, and mRNA vaccines. COVID-19 is an emerging new variant with a different mutation and altered genomic structure. Different pharmacological and therapeutic approaches (interferon, oligonucleotides, anti-viral drug molecules, antibody peptides) have been made so far to combat COVID-19. Interferons are employed in COVID-19 treatment approaches owing to the role of Type I interferons in COVID-19 pathogenesis. Along with these therapeutic methodologies, companies from all over the world participated in the run to develop a vaccine for COVID-19. Vaccines were developed in less than a year for vaccinating humans on a mass level for the first time in world history. These vaccines target structural components of the virus, such as membrane proteins with a spike protein. This article provides valuable information for researchers regarding COVID-19 and progress in therapeutic approaches. This article will serve as a hallmark for understanding the COVID-19 mutation mechanism and strategies to combat these mutation points.